Navigation Links
To treat rare disease, NIH scientists repurpose FDA-approved drug
Date:9/2/2011

WHAT: A new study reports that a drug already approved by the Food and Drug Administration for use in patients undergoing a bone marrow transplant may also have promise for treating people who have a rare immune deficiency known as WHIM syndrome. People with the syndrome are more susceptible to potentially life-threatening bacterial and viral infections, particularly human papillomavirus infections, which cause skin and genital warts and can lead to cancer. The study was conducted by investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Boys and girls are equally at risk of inheriting the genetic mutation that causes WHIM syndrome, and the disorder frequently affects multiple family members. Approximately 60 patients worldwide have been diagnosed with WHIM syndrome, 10 of whom are currently receiving care at NIH.

As a result of the inherited genetic mutation, the function of a molecule, called CXC chemokine receptor 4 (CXCR4), increases. This in turn inhibits migration of neutrophils and other types of white blood cells from the bone marrow into the bloodstream. With fewer circulating immune cells, those with the disorder are less able to fight off infections.

Patients with WHIM syndrome are currently treated with intravenous immunoglobulin, a blood product containing purified human infection-fighting antibodies, and granulocyte colony-stimulating factor, a molecule that stimulates production and maturation of neutrophils. But both therapies are difficult to administer, costly and only partially effective in treating the disease.

The drug tested in the study, known as plerixafor, blocks the activity of CXCR4 and could provide a targeted therapy for this disease. Over a seven-day period, three adult patients with WHIM syndrome were given six injections of increasing doses of plerixafor. The NIAID team observed that the numbers of nearly all immune cell deficiencies in the three patients increased to normal levels, with only minimal adverse side effects at the highest doses.

The investigators say the next step is to determine if long-term use of plerixafor, which is manufactured by Genzyme Corporation (Cambridge, Mass.), is safe and effective in adults. If it is, they will consider conducting clinical studies of plerixafor in children with WHIM syndrome.


'/>"/>

Contact: Julie Wu
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
3. Women More Likely to Fail Treatment for Atrial Fibrillation
4. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Nanofilm Introduces Clarity Defog It™ Anti Fog Treatment and EcoClens™ Eco-Friendly Lens Cleaner at Vision Expo East
7. Many veterans not getting enough treatment for PTSD
8. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
9. Parents often wait too long to treat childrens asthma symptoms
10. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
11. Minorities Not Treated at Higher-Quality Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , ... July 21, 2017 , ... West Dermatology is ... Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large ... of experience in dermatology, skin cancer , and more. She graduated from the ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... concussion rates are on the rise, say researchers presenting their work at the ... Ontario, Canada. , “The combination of evaluating the patterns of change in concussion ...
(Date:7/20/2017)... ... 20, 2017 , ... Acute myeloid leukemia (AML) is a ... without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem cell ... With such a challenging diagnosis that requires immediate action, patients and caregivers need ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays or ... used in such facilities are specially designed to accommodate patients with a wide range ... An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network ... Horine Chiropractic , directed by Dr. Russell Horine, DC to their exclusive list of ... with Dr. Russell Horine serving as the clinic director and his son Dr. Lee ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful carpal tunnel ... syndrome affects more than 8 million people a year. Women suffer ... common methods of treating CTS are painful surgery, the use of ... ... is a clear patch worn on the palm of the hand. ...
(Date:7/11/2017)... Research Corp., also known as ,The Epigenetics Company, announced today the release ... manner using the myDNAge ™ test. Based on Horvath,s Clock, so ... and biostatistics at the David Geffen School of Medicine at UCLA ... DNAge ™ technology is used to analyze DNA methylation patterns of ... ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology: